

Compound

lgG2-B

IqG2-B IgG2-A/B


IgG2-A/B

lgG2-A

IgG2-A

Supelco

UHPLC Analysis of IgG2 on BIOshell™ IgG 1000 Å C4, C18, and Diphenyl, 2.7 µm



column: BIOshell[™] IgG 1000 Å C4, 15 cm x 2.1 mm I.D., 2.7 µm; BIOshell[™] IgG 1000 Å C18,

15 cm x 2.1 mm I.D., 2.7 µm; BIOshell[™] IgG 1000 Å Diphenyl, 15 cm x 2.1 mm I.D., 2.7 µm

Peak Number

1

2

3

4

5

6

mobile phase: [A] 2:10:88 n-propanol/acetonitrile/water (0.1% v/v difluoroacetic acid); [B] 70:20:10 npropanol/acetonitrile/water (0.1% v/v difluoroacetic acid)

gradient:	16%	B to	26%	В	in	20	min
-----------	-----	------	-----	---	----	----	-----

flow rate: 0.2 mL/min

column temp.: 80 °C

detector: UV, 280 nm

injection: 2 µL

sample: Denosumab, 2 mg/mL, water (0.1% v/v trifluoroacetic acid)

Description:

Denosumab is a monoclonal antibody used to treat osteoporosis, hypercalcemia, and bone cancer. The BIOshell™ IqG 1000 Å C4, C18, and Diphenyl phases have unique selectivity for monoclonal antibodies such as denosumab. Each phase is able to successfully separate the disulfide bridge isoforms of the IgG2. Since the retention varies between the three phases, it is recommended to screen them to find the optimal choice for a given monoclonal antibody.

Materials:

Product Part Number	Description		
63289-U	BIOshell™ IgG 1000 Å C4, 15 cm x 2.1 mm I.D., 2.7 μm		
582703-U	BIOshell™ IgG 1000 Å C18, 15 cm x 2.1 mm I.D., 2.7 μm		
577421-U	BIOshell™ IgG 1000 Å Diphenyl, 15 cm x 2.1 mm I.D., 2.7 µm		
00922	Difluoroacetic acid		
302031	Trifluoroacetic acid		
34871	N-propanol		
34851	Acetonitrile		
270733	Water		

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

SigmaAldrich.com